TuHURA Biosciences (NASDAQ:HURA) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

TuHURA Biosciences (NASDAQ:HURA) announced its quarterly earnings data on Friday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04, FiscalAI reports.

TuHURA Biosciences Trading Down 4.3%

NASDAQ HURA traded down $0.06 during trading on Friday, hitting $1.39. The stock had a trading volume of 371,847 shares, compared to its average volume of 853,995. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $88.43 million, a PE ratio of -2.57 and a beta of -0.23. The firm has a 50 day moving average price of $1.93 and a 200 day moving average price of $2.00. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $3.43.

Analyst Ratings Changes

A number of equities analysts have commented on HURA shares. Citizens Jmp reaffirmed a “market outperform” rating and set a $9.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, October 15th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a report on Tuesday, October 27th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

About TuHURA Biosciences

TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.